180 Life Sciences Corp

There is no article text to summarize.

180 Life Sciences Corp has announced a $425 million private placement to advance its Ethereum treasury strategy, marking a significant shift in the company’s financial approach.

180 Life Sciences Corp, a biotech company, has made a bold pivot to cryptocurrency, establishing a $425 million Ethereum treasury and rebranding as ETHZilla in a bid to capitalize on the growing digital asset market.

180 Life Sciences Corp has made a drastic pivot from biotech to cryptocurrency, rebranding as ETHZilla and investing $425 million in an Ethereum treasury in a bid to revive its struggling fortunes.

180 Life Sciences Corp’s stock has plummeted from a 52-week high of $17.75 to $3, highlighting the challenges and risks of biotech investments.

180 Life Sciences Corp is a biotech company dedicated to developing innovative treatments for inflammatory diseases, navigating the challenges and uncertainties of the industry with a focus on innovation and global impact.

180 Life Sciences Corp navigates the challenges and opportunities of the biotech sector, focusing on innovative drugs for inflammatory conditions and positioning itself for long-term success.

180 Life Sciences Corp has announced a patent approval for a cognitive aid post-operation and plans to repurchase 1.32 million shares to simplify its capital structure.